In my current role as Chief Technology Officer at a stealth mode biotech start-up in Cambridge, UK, I lead mRNA vaccine design and manufacture in oncology. I work with consultants, preclinical CROs, and CDMOs to deliver research and clinical-grade mRNA cancer vaccine drug products. I also collaborate with the CSO to generate data for patent and regulatory filings and fund-raising.
Previously, I served as Senior Vice President – Discovery Biology at Ethris GmbH in Planegg, Germany, where I managed discovery research and bioanalytics teams to support the inhaled mRNA therapeutics pipeline. I identified new projects fitting the company’s pulmonary mRNA focus and provided bioanalytics expertise to an antiviral clinical program.
At Atriva Therapeutics GmbH, I was the Chief Scientific Officer and Executive Vice President Pre-Clinical Research, leading pre-clinical research on small molecule host-targeting antiviral agents. I supported clinical research on zapnometinib and developed novel ideas for the clinical application of MEK inhibitors.
As Chief Scientific Officer at MRM Health NV in Ghent, Belgium, I drove the scientific strategy and platform development for orally delivered microbiome therapeutics. I secured over €2m in non-dilutive funding for an innovative microbiome approach to Parkinson’s Disease and managed scientific, research, and technological operations.
During my tenure at CureVac AG in Tübingen, Germany, I was the Vice President and Therapeutic Area Head, Molecular Therapy. I orchestrated the development of mRNA product candidates in various therapeutic areas and managed a multi-million dollar, DARPA-funded international mRNA vaccine project.
Earlier in my career, I held positions at Pike Pharma GmbH, Pfizer Global Research and Development, Valeant Pharmaceuticals, and UC-Irvine. I have a DPhil in Biochemistry from Oxford University and a B.Sc. in Applied and Industrial Biology from South Bank University, London.